The U.S. Food and Drug Administration (FDA) has taken decisive steps to enhance regulatory transparency by initiating real-time public release of complete response letters (CRLs) following their issuance to drug sponsors. This change builds upon the milestone July release of over 200 CRLs and includes an additional 89 letters related to current or withdrawn submissions. The comprehensive disclosures illuminate regulatory rationale behind rejections, including detailed safety and efficacy concerns, exemplified in the letters for Zealand Pharma's glepaglutide and others. This increased openness is set to foster broader industry understanding of FDA decision-making processes and facilitate improved drug development strategies.